Bioscience

ImmuneRegen BioSciences reports positive results from influenza study

November 11, 2009

By Flinn Foundation

[Source: Trading Markets] – ImmuneRegen BioSciences, a wholly owned subsidiary of IR Biosciences Holdings, has reported positive results from a study that evaluated its lead anti-influenza drug, Homspera.

The preclinical study with H5N1 influenza virus, which is highly lethal to humans and animals, revealed that Homspera treatment starting one day following influenza infection dramatically reduced symptoms of influenza infection and increased survival by 60% over infected controls.

For more information: ImmuneRegen BioSciences reports positive results from influenza study